Alnylam Pharmaceuticals (ALNY) Long-Term Investments (2009 - 2026)

Alnylam Pharmaceuticals' Long-Term Investments history runs 18 years deep, the most recent figure standing at $22.2 million for Q1 2026.

• Quarterly Long-Term Investments fell 67.68% year-over-year to $22.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $22.2 million (down 67.68% YoY) and the FY2025 annual result came in at $22.2 million, down 67.68% from the prior year.
• Long-Term Investments was $22.2 million for Q1 2026 at Alnylam Pharmaceuticals, roughly flat from $22.2 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $68.6 million in Q4 2024 and bottomed at $22.2 million in Q4 2025.
• A 5-year average of $50.3 million and a median of $49.4 million in 2022 frame the typical range for Long-Term Investments.
• Annual changes were most pronounced in 2024 — Long-Term Investments soared 38.88% — and 2025, when it sank 67.68%.
• Alnylam Pharmaceuticals' Long-Term Investments stood at $49.4 million in 2022, then rose by 0.0% to $49.4 million in 2023, then surged by 38.88% to $68.6 million in 2024, then sank by 67.68% to $22.2 million in 2025, then changed by 0.0% to $22.2 million in 2026.
• Business Quant data shows ALNY's Long-Term Investments at $22.2 million in Q1 2026, $22.2 million in Q4 2025, and $51.3 million in Q3 2025.